The abstract will be open to public viewing. Submit your abstract between July 1 and July 31, 2025 by 11:59 PM to reserve your spot at the symposium; again, only one form and one presenter per ...

Presenters must provide the name, institution and email of the non-CWRU mentor (and PI if different) with whom they worked. The project mentor (or PI if different) must approve the research ...

The following guidelines specify all aspects of how a good abstract is written. The Title is informative; it is neither too long nor too short, and it does not oversell or sensationalize the content ...

The Program Subcommittee will make these selections randomly to give every submitter who prefers an oral presentation an equal chance of giving one. This decision will be communicated to all ...

Here are some points to consider to localize your presentation: Introduce yourself as a member of the community and emphasize your local connections. Provide personal information that the audience can ...

Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company's lead program ...

This abstract is a sub-study of the TIGeR-PaC clinical trial. The combination product candidate (IAG), which is enabled by the FDA-cleared RenovoCath device, is currently under investigation and ...

Presentations will feature potential best-in-class pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001Erasca will also present ...